Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma
# Background Further research is needed to determine real-world costs of first-line (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), modified FFX (mFFX), and gemcitabine with nab-paclitaxel (GnP). # Objectives To describe healthcare costs by treatment reg...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2025-08-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.142403 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | # Background
Further research is needed to determine real-world costs of first-line (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), modified FFX (mFFX), and gemcitabine with nab-paclitaxel (GnP).
# Objectives
To describe healthcare costs by treatment regimen, stratified by commercial and Medicare Advantage insurance.
# Methods
This retrospective cohort study of adult patients with mPDAC utilized Optum’s de-identified Market Clarity Dataset. Demographics, clinical characteristics, and 1L unadjusted all-cause healthcare costs were examined. Total all-cause costs included costs from inpatient, outpatient, chemotherapy drug and administration, granulocyte colony-stimulating factor (G-CSF), radiation therapy, and other outpatient and pharmacy costs.
# Results
A total of 3115 patients met the criteria for inclusion and received 1L treatment with either FFX, mFFX, or GnP. Among those, 1703 had commercial insurance (FFX, 536; mFFX, 673; GnP, 494) and 1412 had Medicare Advantage (FFX, 201; mFFX, 317; GnP, 894). Total cost of care (mean [SD]) was similar between regimens for each insurance cohort (mean [SD] commercial: FFX, $137 813 [$127 504]; mFFX, $120 109 [$112 208]; GnP, $133 042 [$154 248]; Medicare Advantage: FFX, $110 788 [$98 492]; mFFX, $98 667 [$83 437]; GnP, $110 211 [$100 150]). For both insurance cohorts, chemotherapy drug costs were highest for GnP (mean [SD] commercial: FFX, $10 916 [$21 647]; mFFX, $7653 [$10 054]; GnP, $60 466 [$112 589]; Medicare Advantage: FFX, $8028 [$11 044]; mFFX, $6016 [$7688]; GnP, $49 263 [$49 373]), while chemotherapy administration costs were higher for FFX and mFFX (commercial: FFX, $25 458 [$33 350]; mFFX, $22 795 [$24 309]; GnP $12 206 [$15 766]; Medicare Advantage: FFX, $25 512 [$36 352]; mFFX, $21 524 [$22 317]; GnP $11 103 [$13 089]). G-CSF costs were also higher for FFX and mFFX (commercial: FFX, $38 074 [$56 593], mFFX, $27 823 [$41 166]; GnP, $4029 [$14 181]; Medicare Advantage: FFX, $30 535 [$56 630]; mFFX, $24 596 [$39 286]; GnP, $2412 [$9115]).
# Discussion
Total costs of 1L FFX, mFFX, and GnP were similar within a commercially insured and Medicare Advantage cohort. FFX and mFFX costs were largely driven by chemotherapy administration and G-CSF costs, while GnP costs were driven by chemotherapy drug costs.
# Conclusions
To fully assess the economic impact of mPDAC in 1L treatment, it is essential to consider both the total cost and the individual cost components, such as chemotherapy drugs, administration, and supportive care costs. |
|---|---|
| ISSN: | 2327-2236 |